Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

Sponsor
Bayer
Study ID
NCT02541084
Status
Completed

Conditions

  • Wet Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to proactive therapy especially in real-life rural settings where public transportations are not readily available.

Key Dates

Start date
Aug 18, 2015
Status verified
Aug 2017
Primary completion
Mar 30, 2016
Completion
Jul 30, 2016

Study Design

Enrollment
72 participants (actual)

Arms

  • Arm: PRN group
    wAMD-patients treated with anti-VEGF therapy ´pro re nata´ (PRN)
  • Arm: TAE group
    wAMD-patients treated with anti-VEGF therapy ´treat-and-extend´ (TAE)
  • Arm: PRN-to-TAE switcher group
    wAMD patients treated with anti-VEGF therapy and switching from PRN to TAE regimens

Primary Outcome Measure

Degree of caregiving burden on caregivers (BIC-11) [ Time Frame: At enrollment ]

Related Studies